On September 6, Nathan Hardy notified Sana Biotechnology, that he intends to resign from his position as Executive Vice President and Chief Financial Officer of the Company effective October 4. Hardy resigned voluntarily for personal reasons and not as a result of any disagreement with the company on any matter, including related to the Company’s operations, policies, practices or otherwise.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SANA:
- Sana Biotechnology to Present at September 2024 Investor Conferences
- Sana Biotechnology appoints Dhaval Patel, M.D., CSO
- Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
- Unusually active option classes on open August 22nd
- 3 Small-Cap Stocks with Big Potential, Say Analysts (8/13/24)